BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14), Zacks reports.
BriaCell Therapeutics Stock Down 7.9 %
Shares of NASDAQ:BCTX traded down $0.05 on Monday, reaching $0.61. The company had a trading volume of 2,325,580 shares, compared to its average volume of 1,645,847. The stock has a market capitalization of $22.00 million, a P/E ratio of -0.56 and a beta of 1.46. The stock has a 50-day moving average price of $0.84 and a 200 day moving average price of $0.88. BriaCell Therapeutics has a twelve month low of $0.46 and a twelve month high of $5.97.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of BriaCell Therapeutics in a report on Thursday.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Featured Articles
- Five stocks we like better than BriaCell Therapeutics
- How to Invest in the FAANG Stocks
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- Breakout Stocks: What They Are and How to Identify Them
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
